• 1
    Lusher JM, Salzman PM. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in haemophiliacs previously unexposed to factor VIII C concentrates. Semin Hematol 1990; 27 (Suppl. 2): 17.
  • 2
    Gruppo R, Chen H, Schroth P, Bray GL. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients: a 7.3 year update. Haemophilia 1998; 4: 228 (abstract no. 291, XXIII Congress of the WFH, The Hague).
  • 3
    Lusher J, Abildgaard C, Arkin S, Mannucci PM, Zimmermann R, Schwartz R, Hurst D. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 57483.
  • 4
    Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 14554.
  • 5
    Oldenburg J, Tuddenham E. Genetic basis of inhibitor development in severe haemophilia A and B. In: Rodriguez-MerchanEC, LeeCA, eds. Inhibitors in Patients with Haemophilia. Oxford: Blackwell Science, 2002: 216.
  • 6
    Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 3849.
  • 7
    Strauss HS. Acquired circulating anticoagulants in hemophilia A. New Engl J Med 1969; 281: 866.
  • 8
    Brinkhous KM, Roberts HR, Weiss AE. Prevalence of inhibitors in hemophilia A and B. In: BrinkhousKM, OwrenPA, HinnomS, SurgenorDM, SherryS, StengleJM, eds. Thrombosis: Risk Factors and Diagnostic Approaches. New York: FK Schattauer Verlag, 1972: 31520.
  • 9
    Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 5948.
  • 10
    Sultan Y and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3,435 hemophilia patients in France. Thromb Haemost 1992; 67: 6002.
  • 11
    Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5: 916.
  • 12
    White GCII, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate®) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 6607.
  • 13
    Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Sucrose formulated recombinant human antihemophilic factor VIII is safer and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost 2000; 83: 8116.
  • 14
    Ewenstein B, Collins P, Shapiro A, Tarantino M, Blanchette V, Rogy S, Retzios A, Navale L, Sensel M, Tonetta T, the rAHF-PFM Study Group. Global evaluation of ADVATE rAFF-PFM, an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Blood 2003; 102: 52a (Abstract 172).
  • 15
    Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single centre experience over 34 years, 1964–97. Br J Haematol 1999; 104: 90914.
  • 16
    McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 3448.
  • 17
    Rosendaal FR, Nieuwenhuis HK, Van Den Berg HM, Heijboer H, Mauser-Bunschoten EP, Van Der Meer J, Smit C, Strengers PF, Briet E. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 21806.
  • 18
    Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J. Factor VIII inhibitors in previously treated hemophilia A patients with a double virus-inactivated plasma-derived factor VIII concentrate. Thromb Haemost 1997; 77: 806.
  • 19
    Laub R, DiGiambattista M, Fondu P, Brackmann H-H, Lenk H, Scandella D. Restricted epitope specificity of FVIII inhibitors which appeared in previously treated hemophiliacs after infusion with OCTAVI DS Plus. Thromb Haemost (Congress Suppl.) 2003: 590 (Abstract OC-2409, ISTH Congress, Florence).
  • 20
    White GCII, DiMichele DM, Mertens K, Negrier C, Peake IR, Prowse C, Schwaab R, Yoshioka A, Ingerslev J. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new Factor VIII and Factor IX concentrates. Recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
  • 21
    U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER). Workshop on factor VIII inhibitors, Bethesda, MD, November 21, 2003.